Fresenius Kabi announced July 1 that it has launched its denosumab biosimilars Conexxence and Bomyntra (denosumab-bnht), making it the second biosimilar available in this highly competitive drug category. The drug was approved by the FDA in March 2025.   The denosumab biosimilars expand Fresenius Kabi’s portfolio of marketed biosimilars to 4 drug categories (including pegfilgrastim, … Continue reading Fresenius Kabi Launches the Second Denosumab Biosimilar: Conexxence and Bomyntra, Other Denosumab Launches Pending